Literature DB >> 2081992

Twenty-four-hour ambulatory blood pressure monitoring: a review of validation data.

E O'Brien1, K O'Malley.   

Abstract

As the clinical applications for 24-h ambulatory blood pressure monitoring expand, market demands increase, and there are now at least 13 manufacturers producing elaborate and expensive systems for recording 24-h ambulatory pressures. It is often difficult to assess the accuracy and performance characteristics of these devices and failure to standardize validation makes it difficult to compare one system with another. The standard of the Association for the Advancement of Medical Instrumentation (AAMI) and the recently published protocol of the British Hypertension Society (BHS) provide standardized validation procedures which allow comparisons to be made between ambulatory devices. Thirty-three published reports on 18 ambulatory systems are listed. Five of these systems have been validated according to the AAMI standard; of these, the SpaceLabs 90202 and the Medilog have satisfied the standard, and the Pressurometer IV, the Accutracker II and the Takeda TM-2420 did not satisfy the AAMI standard. The results of recent validations of the SpaceLabs 90207, the Diasys 200, the Takeda TM-2420 and the Pressurometer IV according to the BHS protocol are awaited and should provide further data that will allow comparisons of the performance and the accuracy of different ambulatory systems.

Entities:  

Mesh:

Year:  1990        PMID: 2081992

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  2 in total

1.  Latent overhydration and nocturnal hypertension in diabetic nephropathy.

Authors:  H Mulec; G Blohmé; K Kullenberg; G Nyberg; S Björck
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

2.  The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension.

Authors:  A D Bainbridge; R J Macfadyen; S Stark; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.